Men with stable angina pectoris have a higher incidence of death and heart attack than female patients
Diabetes! previous myocardial infarction! hypertension! and male sex were found to be predictors of cardiovascular mortality (p < 0.001).
Diabetes significantly increased the risk in a small subgroup of women.
Men with stable angina pectoris had a higher mortality rate than men in the reference population (control group) during the first three years (cumulative absolute difference: 3.8%)! while the mortality rate among women with stable angina pectoris was similar to that of women in the control group over the 9.1 years of observation.
The study showed that male patients
With stable angina pectoris! unlike female patients! had a higher mortality rate than men in the reference population.
Diabetes! previous myocardial infarction! hypertension! and being male job function email list were found to be strong risk predictors of cardiovascular death or myocardial infarction.
Previous reports have associated acute coronary syndrome (ACS) with cerebrovascular disease.
However! these data are inconsistent and lack long-term follow-up.
Stroke outcomes from the OPUS-TIMI 16 (Orbofiban in b2c fax Patients with Unstable Coronary Syndromes – Thrombolysis in Myocardial Infarction) study were analyzed.
In the OPUS-TIMI 16 study! patients were randomly assigned to aspirin plus orbofiban or placebo and followed for up to 1 year.
During the 10-month observation period
Risk factors for ischemic stroke (n = 67) and TIA (transient ischemic attack) (n = 44) were age! a previous ischemic stroke! a history of hypertension! and increased heart rate.
A previous ischemic stroke and a history of hypertension tools for evaluating media advertising were not risk factors for ischemic stroke or TIA at 30 days.
Risk factors for intracranial hemorrhage (n = 14) were age! a history of hypertension! a history of TIA! and coronary angiography showing evidence of coronary artery disease.
Compared to placebo! treatment with Orbofiban was associated with a non-significant increased risk of ischemic stroke or TIA (hazard ratio! HR = 1.15; p = 0.51) and intracranial hemorrhage (HR = 1.25; p = 0.70).
The overall incidence of cardiovascular events after acute coronary syndrome was highest in the first 30 days and declined thereafter.
Orbofiban was not effective in preventing ischemic stroke or TIA.